Role of anthracyclines in neoadjuvant anti-HER2 regimens for HER2+ breast cancer (BC): A network meta-analysis (NMA). This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This ...
Genomically Basal-Type tumors demonstrate distinct immune profiles and chemosensitivity across self-reported race among patients enrolled in FLEX receiving neoadjuvant chemotherapy In this real-world ...
Additional research highlights integration of BluePrint molecular subtyping and ImPrint immune profiling to optimize prediction of neoadjuvant treatment response in HER2-positive early-stage breast ...
Genomic assays have become indispensable tools in the management of early-stage invasive breast cancer, helping oncologists ...
MammaPrint effectively predicts chemotherapy benefit and distant recurrence-free interval in HR+HER2- early breast cancer. High-risk patients benefit significantly from chemotherapy, while low-risk ...
"We hope to assess the utility of gene expression profiling with our platform as a predictive biomarker for the benefit of other emerging therapies in breast cancer." — William Audeh, MD, MS, Chief ...
IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia ®, Inc. today provided a topline review of the company’s key milestone achievements in 2024. These updates include significant inroads in expanding ...
Agendia will present two posters highlighting how its tests provide insights into treatment response and aid therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results